1068515-64-9Relevant academic research and scientific papers
Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)
Cadieux, Jay A.,Zhang, Zaihui,Mattice, Maryanne,Brownlie-Cutts, Alison,Fu, Jianmin,Ratkay, Laszlo G.,Kwan, Rainbow,Thompson, Jay,Sanghara, Joseph,Zhong, Jing,Goldberg, Y. Paul
scheme or table, p. 90 - 95 (2012/02/16)
Three distinct series of substituted pyrazole blockers of divalent metal transporter 1 (DMT1) were elaborated from the high-throughput screening pyrazolone hit 1. Preliminary hit-to-lead efforts revealed a preference for electron-withdrawing substituents in the 4-amido-5-hydroxypyrazole series 6a-l. In turn, this preference was more pronounced in a series of 4-aryl-5- hydroxypyrazoles 8a-j. The representative analogs 6f and 12f were found to be efficacious in a rodent model of acute iron hyperabsorption. These three series represent promising starting points for lead optimization efforts aimed at the discovery of DMT1 blockers as iron overload therapeutics.
PYRAZOLE AND PYRROLE COMPOUNDS USEFUL IN TREATING IRON DISORDERS
-
Page/Page column 87, (2008/12/04)
This invention is directed to pyrazole and pyrrole compounds, for example, compounds of formula (I): wherein R1, R2, R3 and R4 are as defined herein, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.
